Efficacy of adalimumab in Korean patients with Crohn's disease

Il Woong Sohn, Sung Tae Kim, Bun Kim, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, JaeHee Cheon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background/Aims: Adalimumab is effective for both remission induction and the maintenance of Crohn's disease (CD) in Western countries. We evaluated the efficacy of adalimumab in the conventional step-up treatment approach for CD in Korea. Methods: We retrospectively reviewed 62 patients with CD who were treated with adalimumab. Their Crohn's disease activity index (CDAI) was measured at weeks 4, 8, and 52. Clinical remission was defined as a CDAI score <150. Induction and maintenance outcomes were analyzed. Results: Forty-one patients (66.1%) achieved a reduction of 70 CDAI points at week 8. Among them, 28 (45.2%) achieved clinical remission at week 8, 20 (32.3%) maintained remission at week 52. The absence of prior anti-tumor necrosis factor (TNF) therapy and Montreal classification L1 at baseline predicted clinical remission at week 8 in the multivariate logistic regression analysis. In the Cox proportional hazards model, the hazard ratio for the secondary loss of response during maintenance therapy after clinical remission induction was significantly higher in patients who showed initial mild CDAI severity or Montreal classification A3. Conclusions: In our study, anti-TNF therapy-naive and Montreal classification L1 were associated with adalimumab efficacy as induction therapy in CD. Further studies are warranted to determine the prognostic factors for the long-term response after adalimumab therapy.

Original languageEnglish
Pages (from-to)255-261
Number of pages7
JournalGut and Liver
Volume10
Issue number2
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Crohn Disease
Remission Induction
Therapeutics
Tumor Necrosis Factor-alpha
Maintenance
Adalimumab
Korea
Proportional Hazards Models
Logistic Models
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Sohn, I. W., Kim, S. T., Kim, B., Lee, H. J., Park, S. J., Hong, S. P., ... Cheon, J. (2016). Efficacy of adalimumab in Korean patients with Crohn's disease. Gut and Liver, 10(2), 255-261. https://doi.org/10.5009/gnl15165
Sohn, Il Woong ; Kim, Sung Tae ; Kim, Bun ; Lee, Hyun Jung ; Park, Soo Jung ; Hong, Sung Pil ; Kim, Tae Il ; Kim, Won Ho ; Cheon, JaeHee. / Efficacy of adalimumab in Korean patients with Crohn's disease. In: Gut and Liver. 2016 ; Vol. 10, No. 2. pp. 255-261.
@article{b8d0d0dd947b4c489f84be1a0e5987b1,
title = "Efficacy of adalimumab in Korean patients with Crohn's disease",
abstract = "Background/Aims: Adalimumab is effective for both remission induction and the maintenance of Crohn's disease (CD) in Western countries. We evaluated the efficacy of adalimumab in the conventional step-up treatment approach for CD in Korea. Methods: We retrospectively reviewed 62 patients with CD who were treated with adalimumab. Their Crohn's disease activity index (CDAI) was measured at weeks 4, 8, and 52. Clinical remission was defined as a CDAI score <150. Induction and maintenance outcomes were analyzed. Results: Forty-one patients (66.1{\%}) achieved a reduction of 70 CDAI points at week 8. Among them, 28 (45.2{\%}) achieved clinical remission at week 8, 20 (32.3{\%}) maintained remission at week 52. The absence of prior anti-tumor necrosis factor (TNF) therapy and Montreal classification L1 at baseline predicted clinical remission at week 8 in the multivariate logistic regression analysis. In the Cox proportional hazards model, the hazard ratio for the secondary loss of response during maintenance therapy after clinical remission induction was significantly higher in patients who showed initial mild CDAI severity or Montreal classification A3. Conclusions: In our study, anti-TNF therapy-naive and Montreal classification L1 were associated with adalimumab efficacy as induction therapy in CD. Further studies are warranted to determine the prognostic factors for the long-term response after adalimumab therapy.",
author = "Sohn, {Il Woong} and Kim, {Sung Tae} and Bun Kim and Lee, {Hyun Jung} and Park, {Soo Jung} and Hong, {Sung Pil} and Kim, {Tae Il} and Kim, {Won Ho} and JaeHee Cheon",
year = "2016",
month = "3",
day = "1",
doi = "10.5009/gnl15165",
language = "English",
volume = "10",
pages = "255--261",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "2",

}

Sohn, IW, Kim, ST, Kim, B, Lee, HJ, Park, SJ, Hong, SP, Kim, TI, Kim, WH & Cheon, J 2016, 'Efficacy of adalimumab in Korean patients with Crohn's disease', Gut and Liver, vol. 10, no. 2, pp. 255-261. https://doi.org/10.5009/gnl15165

Efficacy of adalimumab in Korean patients with Crohn's disease. / Sohn, Il Woong; Kim, Sung Tae; Kim, Bun; Lee, Hyun Jung; Park, Soo Jung; Hong, Sung Pil; Kim, Tae Il; Kim, Won Ho; Cheon, JaeHee.

In: Gut and Liver, Vol. 10, No. 2, 01.03.2016, p. 255-261.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of adalimumab in Korean patients with Crohn's disease

AU - Sohn, Il Woong

AU - Kim, Sung Tae

AU - Kim, Bun

AU - Lee, Hyun Jung

AU - Park, Soo Jung

AU - Hong, Sung Pil

AU - Kim, Tae Il

AU - Kim, Won Ho

AU - Cheon, JaeHee

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background/Aims: Adalimumab is effective for both remission induction and the maintenance of Crohn's disease (CD) in Western countries. We evaluated the efficacy of adalimumab in the conventional step-up treatment approach for CD in Korea. Methods: We retrospectively reviewed 62 patients with CD who were treated with adalimumab. Their Crohn's disease activity index (CDAI) was measured at weeks 4, 8, and 52. Clinical remission was defined as a CDAI score <150. Induction and maintenance outcomes were analyzed. Results: Forty-one patients (66.1%) achieved a reduction of 70 CDAI points at week 8. Among them, 28 (45.2%) achieved clinical remission at week 8, 20 (32.3%) maintained remission at week 52. The absence of prior anti-tumor necrosis factor (TNF) therapy and Montreal classification L1 at baseline predicted clinical remission at week 8 in the multivariate logistic regression analysis. In the Cox proportional hazards model, the hazard ratio for the secondary loss of response during maintenance therapy after clinical remission induction was significantly higher in patients who showed initial mild CDAI severity or Montreal classification A3. Conclusions: In our study, anti-TNF therapy-naive and Montreal classification L1 were associated with adalimumab efficacy as induction therapy in CD. Further studies are warranted to determine the prognostic factors for the long-term response after adalimumab therapy.

AB - Background/Aims: Adalimumab is effective for both remission induction and the maintenance of Crohn's disease (CD) in Western countries. We evaluated the efficacy of adalimumab in the conventional step-up treatment approach for CD in Korea. Methods: We retrospectively reviewed 62 patients with CD who were treated with adalimumab. Their Crohn's disease activity index (CDAI) was measured at weeks 4, 8, and 52. Clinical remission was defined as a CDAI score <150. Induction and maintenance outcomes were analyzed. Results: Forty-one patients (66.1%) achieved a reduction of 70 CDAI points at week 8. Among them, 28 (45.2%) achieved clinical remission at week 8, 20 (32.3%) maintained remission at week 52. The absence of prior anti-tumor necrosis factor (TNF) therapy and Montreal classification L1 at baseline predicted clinical remission at week 8 in the multivariate logistic regression analysis. In the Cox proportional hazards model, the hazard ratio for the secondary loss of response during maintenance therapy after clinical remission induction was significantly higher in patients who showed initial mild CDAI severity or Montreal classification A3. Conclusions: In our study, anti-TNF therapy-naive and Montreal classification L1 were associated with adalimumab efficacy as induction therapy in CD. Further studies are warranted to determine the prognostic factors for the long-term response after adalimumab therapy.

UR - http://www.scopus.com/inward/record.url?scp=84960491191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960491191&partnerID=8YFLogxK

U2 - 10.5009/gnl15165

DO - 10.5009/gnl15165

M3 - Article

C2 - 26470766

AN - SCOPUS:84960491191

VL - 10

SP - 255

EP - 261

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 2

ER -

Sohn IW, Kim ST, Kim B, Lee HJ, Park SJ, Hong SP et al. Efficacy of adalimumab in Korean patients with Crohn's disease. Gut and Liver. 2016 Mar 1;10(2):255-261. https://doi.org/10.5009/gnl15165